for the Insulin Resistance Intervention After Stroke (IRIS) Trial Investigators IMPORTANCE There is growing recognition that patients may respond differently to therapy and that the average treatment effect from a clinical trial may not apply equally to all candidates for a therapy.
The challenge of estimating the benefits and risks of medical therapy is not new, and the field of clinical therapeutics has long recognized that treatments may work differently in different groups of patients, a concept known as heterogeneity of treatment effect. 4, 5 Investigators often discover heterogeneity by examining treatment effect for subgroups defined by single variables in completed clinical trials. However, multivariable risk stratification systems more effectively stratify patients by their pretreatment risk and may be more effective in identifying groups of patients for whom an intervention offers particular benefit. 5 Recent examples include research suggesting that lung cancer screening has a greater net benefit for patients with a higher baseline risk for cancer, 6 that lifestyle modification is more effective in preventing diabetes in patients at highest risk for diabetes, 7 and that dual antiplatelet therapy beyond 1 year for patients with a coronary stent is more effective for patients with a higher risk for thrombosis. 8 Heterogeneity may be observed on relative scales (eg, the hazard ratio [HR] may differ between subgroups) or absolute scales (eg, outcome rates may differ). As in the examples already given, however, heterogeneity is far more commonly found for absolute scales than for relative scales. Analyses for heterogeneity of treatment effect on relative and absolute scales are usually performed in clinical trial cohorts. Pretreatment risk of disease may be stratified by applying published systems or, if these are not available, by applying a system that is internally derived from the trial population. Evidence from theory and simulations show that such internal risk stratification systems do not introduce bias in treatment effect estimates across risk strata when compared with external models. 9 The purpose of this study was to estimate the relative and absolute effectiveness of pioglitazone after ischemic stroke or TIA in subgroups of patients defined by pretreatment risk for stroke or MI. This analysis was not prespecified in the Insulin Resistance Intervention After Stroke (IRIS) trial protocol. 10 However, the methods were developed and approved by the authors before conducting the analysis.
Methods

Participants
The design of the IRIS trial has been previously published. 10 In brief, IRIS was a randomized, double-blind, placebocontrolled clinical trial that tested pioglitazone for prevention of stroke and MI among patients with insulin resistance but without type 1 or type 2 diabetes who had an ischemic stroke or TIA within 180 days of trial entry. Major exclusion criteria were being younger than 40 years of age and a history of heart failure or bladder cancer. Between February 7, 2005, and January 15, 2013, a total of 3876 participants were enrolled from 179 clinical sites in 7 countries. Institutional review boards approved the protocol at each site prior to data collection. Written informed consent was obtained from the participants.
Follow-up Procedures
Participants were randomized to receive pioglitazone hydrochloride at an initial daily dose of 15 mg or matching placebo. Follow-up contacts to inquire about health events took place every 2 weeks for 3 months while the dose was increased to 45 mg of pioglitazone hydrochloride or matching placebo. Thereafter, participants were contacted every 4 months up to a maximum follow-up of 5 years or at the last scheduled contact before study end on July 28, 2015.
2 Mean follow-up for participants was 4.1 years.
Internally Derived Risk Models
We used the IRIS internal whole-trial data (ie, pioglitazone and placebo groups combined) to identify subgroups with a distinct risk for stroke or MI. 9 This approach avoids differential fitting on treatment and control groups, which can induce bias in estimation of treatment effect across risk strata. 9 Predictive features included pretreatment variables known to be associated with increased risk for stroke or MI after an index stroke and that were available in the IRIS data set. These features included age, atrial fibrillation, stroke mechanism, stroke vs TIA for the index event, history of stroke before index event, motor weakness, aphasia, coronary artery disease, history of hypertension, systolic blood pressure, peripheral arterial disease, and current smoking status. [11] [12] [13] [14] [15] Because patients with diabetes were excluded from the IRIS trial, hemoglobin A 1c level was examined as a continuous variable. In addition, we included 2 features that we hypothesized might be associated with risk for stroke or MI: sex and modified Rankin Scale score. Two risk stratification systems were created from these variables: model A (the main system) and model B (the supplemental system). For model A, risk of stroke or MI was estimated for each participant in a Cox proportional hazards re-gression model that included all the predictive variables listed. This estimated risk was used to assign participants to risk quantiles. We examined halves, tertiles, quartiles, and quintiles but reported selectively based on risk distribution and the number of outcomes per quantile, but not on treatment effect. Performance metrics for model A included the C statistic, the extreme quantile risk ratio, and the median to mean risk ratio. 16 After stratifying participants into quantiles of predicted risk from model A, we calculated the ratio of highestrisk to lowest-risk quantile predicted risk and the ratio of highest-risk to lowest-risk quantile observed risk. The extreme quantile risk ratios increase with greater risk heterogeneity in the patient population. The ratio of median to mean predicted risk is a measure of skewness in risk, with larger values reflecting greater divergence between the mean result and the risk for a typical patient. Model B was developed contingent on finding heterogeneity of treatment effect on either relative or absolute scales from model A. To create model B, the predictive variables included in model A were entered into a Cox proportional hazards regression model, and a backward selection procedure was used to remove features not significantly associated with risk (P < .05). The model coefficients were used to assign scores to the selected features, and risk groups were defined by summing scores. No imputations were made for missing data. Performance metrics for model B included the C statistic and extreme quantile risk ratios. As a check on external validity, we also examined the discrimination of model B using data from the Women's Estrogen for Stroke Trial (WEST).
17 (The WEST trial lacked several variables needed to test model A.)
Externally Derived Risk Model
We identified an external risk stratification system in a literature search for articles that developed or evaluated prediction models meeting the following criteria: (1) they included adult patients with ischemic stroke or TIA, (2) they combined multiple predictor variables, (3) they included recurrent stroke as an outcome, (4) they predicted risk over at least 1 year, and (5) they maintained predictive value in an external cohort. Among the 3 eligible models identified in our search, 11,18-20 the Stroke Prognosis Instrument II (SPI-II) was chosen for its marginally superior discriminative performance and its usability as a simple point score. 19, 21 The C statistic was again used to quantify the discrimination of SPI-II in the IRIS cohort.
Statistical Analysis
All analyses of heterogeneity of treatment effect were conducted using the "as randomized" principle (intention to treat). Within each risk stratum for models A and B and SPI-II, treatment effects on risk for stroke or MI were estimated on relative and absolute scales. Relative effects were estimated by HRs from the Cox proportional hazards regression. The absolute risk difference (ARD) was calculated as the difference in KaplanMeier 5-year survival probabilities between the pioglitazone and placebo groups. The number needed to be treated was derived from these same probabilities. The null hypothesis of no heterogeneity of treatment effect across risk strata was tested in Cox proportional hazards regression models that included the indicator variable for risk group, treatment, and a product term ("interaction") between risk group and treatment. An interaction term significant at P < .05 would indicate the presence of heterogeneity of treatment effect on a relative scale (ie, in HRs). Secondary outcomes examined by treatment group within risk strata were stroke alone, acute coronary syndrome, allcause mortality, and selected adverse events that have been associated with pioglitazone (ie, heart failure, bone fracture, and weight gain). We used SAS software, version 9.3, for all analyses (SAS Institute Inc).
Results
Study Population
There were 3876 total participants (1939 randomly assigned to pioglitazone and 1937 randomly assigned to placebo) enrolled in this study (1338 women 
Internally Derived Risk Model A
The following 6 features were significantly associated with increased risk for stroke or MI: aphasia, coronary artery disease, hypertension history, current smoking, peripheral arterial disease, and older age (eTable 1 in the Supplement). The model containing all 15 risk features had a C statistic of 0.66. Predicted risk estimates for the cohort were slightly skewed (median, 10.8%; mean, 12.3%; median to mean ratio, 0.88). Stratification of patients into 2 groups (above and below the median) and tertiles resulted in a 2-to 3-fold increase in both observed and predicted risk from lowest to highest strata (eTable 2 in the Supplement). (Greater quantiles were not reported owing to limitations on events per strata.) We present the main results below in groups defined by median risk. Similar results by risk tertiles are included in eTable 3 in the Supplement.
Among patients with lower risk, the 5-year risk for stroke or MI was 6.0% in the pioglitazone group vs 7.9% in the placebo group (ARD, -1.9% [95% CI, -4.4% to 0.6%]; HR, 0.77 [95% CI, 0.53 to 1.11]). For patients with higher risk, the 5-year risk for stroke or MI was 14.7% in the pioglitazone group vs 19.6% in the placebo group (ARD, -4.9% [95% CI, -8.6% to -1.2%]; HR, 0.75 [95% CI, 0.60 to 0.95]) (Figure, Table 2 ;eTable3intheSupplement). The HRs for the 2 risk groups were not significantly different (P = .92).
For the secondary efficacy outcomes of stroke alone and acute coronary syndrome, similar findings were observed. The ARDs were higher for the higher-risk groups, but the HRs were similar. The ARDs were identical for all-cause mortality.
For adverse events, the risk increments for heart failure and weight gain were slightly lower in the high-risk group than in the low-risk group, but the risk increment for bone fracture was higher. The risk for fracture was 10.6% in the pioglitazone group vs 7.4% in the placebo group (ARD, 3.2% [95% CI, 0.4%-6.0%]; HR, 1.40 [95% CI, 1.01-1.94]) among patients at lower pretreatment risk for stroke or MI. The risk for fracture was 16.9% in the pioglitazone group vs 10.1% in the placebo group (ARD, 6.8% [95% CI, 3.3%-10.2%]; HR, 1.65 [95% CI, 1.25-2.17]) among patients at higher risk for stroke or MI.
To understand the finding for bone fracture, we examined the risk for fracture for the features in Table 1 . As expected, age was strongly associated with both increased risk for stroke and MI and risk for fracture. In addition, 2 features associated with risk for stroke and MI, prior stroke and aphasia, displayed an interactive effect between treatment and fracture risk: the presence of both was associated with greater fracture risk in the pioglitazone group but not in the placebo group (eTable 4 in the Supplement).
Internally Derived Risk Model B
Predictive features selected for model B are shown in Table 3 . The C statistic for the model was 0.65. The observed risk for stroke or MI increased 2-to 3-fold from the lowest to the highest quantile. When model B was tested using the WEST data, outcome rates were 17.1% for 181 patients with a score of 0 to 1 compared with 23.5% for 476 patients with a score of 2 or more (HR, 1.42 [95% CI, 0.96-2.12]) (eTable 5 in the Supplement). The C statistic in WEST was 0.59.
The risk-stratified findings in model B were similar to those in model A for the primary outcome (Table 4 ; eFigure and eTable 6 in the Supplement). That is, the ARD for stroke or MI was more than 2-fold higher among patients at high pretreatment risk compared with patients at lower pretreatment risk (-4.8% [95% CI, -8.7% to -0.9%] vs -2.0% [95% CI, -4.3% to 0.3%]), but the HRs were similar. Some differences between models A and B were observed for secondary efficacy outcomes. In particular, the ARD for stroke alone was identical for the 2 risk groups in model B (-1.7%). As in model A, the ARD for fracture was higher for patients with a high pretreatment risk for stroke or MI.
External Risk Model
When we repeated the analysis using the SPI-II instrument (eTable 7 in the Supplement), results were similar to those from the internal models (eTable 8 in the Supplement). However, the increment in fracture risk was less between the high-and lowrisk groups for SPI-II compared with model A (1.7% vs 3.6%). 
Discussion
For this analysis, we created a system to divide the IRIS trial population into 2 subpopulations of equal size with a high (17.2%) and low (6.9%) 5-year risk for stroke or MI. The relative risk reduction for stroke or MI with pioglitazone was similar in the group at high risk and the group at low risk (ie, HR, 0.75 vs 0.77). Because of effective risk stratification and stable relative risk reduction across risk groups, the absolute risk reduction was substantially larger (4.9%) for patients at high pretreatment risk compared with those at low pretreatment risk (1.9%). In terms of the number needed to be treated, 21 high-risk patients would need to be treated for approximately 5 years to prevent 1 stroke or MI compared with 53 low-risk patients. Our finding of no substantial differences in relative risk reduction between the high-and low-risk groups (ie, homogeneity in relative treatment effect) is common and represents the rule rather than the exception in treatment research. In a recent reanalysis of participant data from 18 large trials with statistically significant treatment effects, statistically significant heterogeneity of relative risk reduction was observed in only 1 trial, but clinically meaningful distinctions in absolute risk reduction (ie, heterogeneity in absolute treatment effect) were common when patients were risk stratified. 16 This pattern illustrates the important added meaning of data on absolute risk reduction. Patients who experience the same relative risk reduction with a therapy may experience a very different absolute benefit depending on underlying risk. For this reason, broader use of data on absolute risk reduction (in the form of natural frequency information) has been advocated to enhance communication with patients about the benefits and risks of specific therapy.
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The use of pretreatment risk to identify patients most likely to benefit from preventive therapy is a form of personalized medicine that is gaining increasing attention in patient care. disease advocate the use of this therapy only for patients whose 10-year risk for major cardiovascular disease exceeds a specific threshold as determined by the pooled cohort equation and other considerations. Guidelines for aspirin therapy and anticoagulation for atrial fibrillation take similar approaches. 25, 26 To our knowledge, our analysis is one of a very few 27, 28 to apply this concept of risk-based treatment selection to the field of stroke prevention and is the first to examine it in the context of the cardiovascular benefit of pioglitazone. Our results may be helpful to future committees that make recommendations for the use of this novel therapy. In the IRIS trial, patients at high baseline risk experienced greater benefit from pioglitazone in terms of prevention of stroke and MI but also experienced a higher absolute risk increment for bone fracture compared with patients at low baseline risk (6.8% vs 3.2%). The reason for this increment in bone fracture absolute risk was identified in an exploratory analysis (eTable 4 in the Supplement). Three factors used to model risk for stroke and MI were also associated with quantitatively important increases in risk for fracture: older age, prior stroke, and aphasia (although the test for interaction was only significant for prior stroke). The association with age is well documented for both conditions. The finding that patients with prior stroke or possibly aphasia experienced a higher fracture risk in the pioglitazone group but a lower risk in the placebo group needs exploration in other populations to determine if this result was a chance finding in our data or a true and heretofore unidentified interaction effect.
As a summary metric of benefit compared with harm, we used the data in Table 2 and Table 4 to calculate the number of bone fractures per stroke or MI prevented. This ratio was greater than 1 in each stratum but decreased from 1.7 in the lowrisk stratum to 1.4 in the high-risk stratum for model A and from 1.6 to 1.4 for the same strata in model B. This simple analysis ignores the relative importance that patients may assign to fractures compared with myocardial and cerebral events.
Strengths and Limitations
The strengths of our study include the high quality of the IRIS trial data, including pretreatment risk data and ascertainment of outcome events. 2, 29 The limitations of our analysis include the fact that it was not prespecified before the trial was completed. We attempted to mitigate this weakness by writing the analytic protocol before conducting the analysis. Second, the number of trial participants was not large enough to support every subgroup analysis or to avoid all possible error in the selection of risk factors. In particular, the sample size limited the power to detect statistically significant differences between HRs and risk differences. Finally, to our knowledge, the IRIS trial is the only randomized clinical trial of pioglitazone after stroke or TIA; therefore, our findings cannot yet be independently verified. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
